October 8-10, 2024 – CPHI Worldwide 2024, the premier pharmaceutical event globally, took place successfully in Milan, Italy. Gan & Lee Pharmaceuticals (referred to as Gan & Lee, stock code: 603087. SH) was among the distinguished contingent of over 2,400 exhibitors at CPHI Milan 2024. The event drew a global audience of more than 62,000 pharmaceutical experts, creating a significant industry gathering.

At CPHI Worldwide 2024, the Gan & Lee contingent actively engaged in meaningful and productive discussions with delegates from a variety of backgrounds. The team successfully established connections with numerous esteemed global companies during these interactions. Additionally, they took the opportunity to showcase the latest developments in Gan & Lee’s product pipeline, while also delineating their strategies for international market expansion. Through these endeavors, the company has further solidified its foundation, paving the way for an even deeper penetration into the global market.

With a steadfast focus on patient needs, Gan & Lee is dedicated to advancing the local manufacturing of insulin in a growing number of countries, contributing to the reduction of drug costs, and delivering more extensive, effective, and tailored medical care solutions to patients globally. At the event, Gai Liu, the company's Director of International Business, commented in a media interview: "It's a privilege to be part of this esteemed event. Since its inception in 1998, Gan & Lee has made significant strides in innovation and growth. Our product range now includes second to fourth-generation diabetes treatments. Moreover, through partnerships with international pharmaceutical firms like Sandoz, we are proactively entering developed markets and simultaneously expanding in emerging markets with our key partners, spanning Europe, Asia, Africa, and Latin America. Looking ahead, we are committed to increasing our investment in research and development to bolster our innovation capacity and provide more potent and high-quality medications to patients around the world."

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^?), fast-acting lispro injection (Prandilin^?), fast-acting aspart injection (Rapilin^?), mixed protamine zinc lispro injection (25R) (Prandilin^?25), aspart 30 injection (Rapilin^?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^?30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^?).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^?) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.